Punit Dhillon - OncoSec Medical Co-Founder, CEO and President and Director

Mr. Punit S. Dhillon is Director of OncoSec Medical Incorporated. He was appointed Chief Executive Officer. Mr. Dhillon was formerly Vice President of Finance and Operations at Inovio from September 2003 until March 2011. In his management experience, Mr. Dhillon has raised over 160 million through multiple financings and several outlicensing deals including early stage deals with Merck and Wyeth . Mr. Dhillon was responsible for implementation of Inovios corporate strategy. He was also instrumental to the successful inlicensing of key intellectual property and a number of corporate transactions, including the acquisition and consolidation of Inovio AS, a Norwegian DNA delivery company, and the merger and postmerger integration with VGX Pharmaceuticals, Inc. Mr. Dhillons management experience spans corporate finance, MA, integration, successful inlicensing of key intellectual property, strategy implementation, corporate transactions with industry, and collaborations with leading academic institutions across the globe. Mr. Dhillon is currently a board member of Emerald Health Therapeutics, Inc., a TSX Venture Exchange listed company. Mr. Dhillon has also previously been a consultant and board member for several TSX Venture Exchange listed early stage life science companies, which matured through advances in their development pipelines and subsequent MA transactions. Prior to joining Inovio, Mr. Dhillon worked for a corporate finance law firm as a law clerk. From September 1999 to July 2002, he worked with MDS Capital Corporationration as an intern analyst since 2018.